BioAmber (NYSE: BIOA) reported Q3 EPS of ($0.16), $0.16 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $3.3 million versus the consensus estimate of $6.75 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.